BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Biovest International, Inc. 

Corporate Headquarters
8500 Evergreen Blvd. NW
Minneapolis  Minnesota  55433  U.S.A.
Phone: 763-786-0302 Fax: 763-786-0915


SEARCH JOBS

View Clinical Trials from BioPharm Insight



Industry
Biotechnology






 Company News
Biovest International, Inc. CEO Carlos F. Santos, Ph.D. To Present At The Phacilitate Immunotherapy Forum 1/27/2014 9:30:09 AM    More...
European Medicines Agency Accepts Marketing Authorization Application For Biovest International, Inc.’s Cancer Vaccine For Treatment Of Non-Hodgkin’s Follicular Lymphoma 1/13/2014 10:57:09 AM    More...
Biovest International, Inc. Emerges From Bankruptcy and Taps New CEO 7/16/2013 7:04:30 AM    More...
Request to Appoint Tustee or Examiner in Biovest International, Inc. Case Denied 4/16/2013 8:58:43 AM    More...
Biovest International, Inc. Files for Bankruptcy 3/8/2013 8:20:58 AM    More...
Accentia Biopharmaceuticals (ABPI), Biovest International, Inc. Shrink Losses, Default on Debt 12/27/2012 8:16:32 AM    More...
Biovest International, Inc. Names Lymphoma Key Opinion Leader From MD Anderson Cancer Center to Scientific Advisory Board 9/11/2012 10:13:57 AM    More...
Biovest International, Inc. Conducts End of Phase III Review With FDA of BiovaxID™ as Consolidation Therapy in Non-Hodgkin's Lymphoma 8/14/2012 9:03:40 AM    More...
Biovest International, Inc. Advances Process Seeking European Marketing Approval for BiovaxID™ Personalized Lymphoma Vaccine 7/30/2012 10:02:38 AM    More...
Biovest International, Inc. Release: National Cancer Institute Study Demonstrates Significant Overall Survival and Time-to-Next-Treatment Benefits for BiovaxID® Cancer Vaccine Following Rituximab-Chemotherapy in Mantle Cell Lymphoma Study 6/7/2012 10:05:43 AM    More...
12345678910